Form 8-K - Current report:
SEC Accession No. 0001213900-24-076108
Filing Date
2024-09-05
Accepted
2024-09-05 16:15:10
Documents
15
Period of Report
2024-09-05
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0213639-8k_citius.htm   iXBRL 8-K 27933
2 PRESS RELEASE DATED SEPTEMBER 5, 2024 ea021363901ex99-1_citius.htm EX-99.1 36236
3 GRAPHIC ex99-1_001.jpg GRAPHIC 12286
  Complete submission text file 0001213900-24-076108.txt   265285

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ctxr-20240905.xsd EX-101.SCH 3027
5 XBRL LABEL FILE ctxr-20240905_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE ctxr-20240905_pre.xml EX-101.PRE 22367
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0213639-8k_citius_htm.xml XML 3685
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38174 | Film No.: 241281580
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)